A big deal in biotech is going to line the pockets of some of Wall Street's biggest firms.
ADVERTISEMENT
Some of Wall Street's biggest firms just landed a big pay day (PTHN)
A big deal in biotech is going to line the pockets of some of Wall Street's biggest firms.
ADVERTISEMENT
The biotech company Thermo Fisher Scientific has agreed to buy the drug-ingredients maker Patheon in a $7.2 billion deal.
In a statement Monday, Thermo Fisher said it would acquire all outstanding Patheon shares for $35 apiece in cash, 35% higher than where the stock closed Friday.
One of Patheon's biggest backers, JLL Partners, a Chicago-based private equity firm, stands to make a killing from the deal. According to reporting by Bloomberg, affiliates of JLL could earn $2.2 billion, or nearly five times the original $462 million they invested in March 2014 prior to the company's initial public offering.
ADVERTISEMENT
Two of Wall Street's fiercest rivals also stand to profit from the acquisition.
On the buy-side of the deal, Goldman Sachs advised Thermo Fisher and could rake in $30 million, according to data from Freeman & Co.
On the sell-side, Morgan Stanley served as Patheon's adviser and could make $35 million.
The deal is expected to close by the end of 2017.
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
How SafeHamsters unlocks the potential of crypto betting| Insider Tips
A look into the diverse tax reforms being implemented across Africa
Dubai firm to lend South Sudan $12.9 billion in exchange for 20 years oil repayment
China dethrones USA as the most influential global power in Africa: Report
Major African economies expecting inflation ease into next year, except Nigeria
10 African countries with the lowest price changes in household commodities
Dangote refinery outranks Europe's 10 largest refining facilities
Africa may just have the lowest level of cyber threats compared to other regions